This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fidler, I. J. Articles by Bucana, C. Search for Related Content PubMed PubMed Citation Articles by Fidler, I. J. Articles by Bucana, C.

Mechanism of Tumor Cell Resistance to Lysis by Syngeneic Lymphocytes¹

Basic Research Program, National Cancer Institute Frederick Cancer Research Center, Frederick, Maryland 21701

B16 melanoma variant lines, which resisted lysis by syngeneic lymphocytes, were selected in vitro by repeated exposure of the tumor cells to purified cytotoxic lymphocytes. The resistance of the tumor cells to lysis mediated by syngeneic lymphocytes was not accompanied by a loss or masking of major histocompatibility antigens. Neither the lymphocyte-susceptible B16 (F10) nor the lymphocyte-resistant B16 (F10^Lr) cells grew in allogeneic recipients, and both were destroyed in vitro by allogeneic lymphocytes. The resistance to lysis by syngeneic lymphocytes was not accompanied by loss or masking of receptors for macrophage recognition and destruction. F10^Lr cells did not protect F10 cells from lymphocyte-mediated lysis in cocultivation experiments. Immunization of syngeneic mice in vivo with B16-F10 cells successfully protected mice against challenge with B16-F10 cells. However, mice immunized with B16-F10^Lr cells were not protected against challenge with B16-F10 cells. B16-F10^Lr cells were not immunogenic when tested under this condition. Light, scanning, and transmission electron microscopic studies of tumor cell-lymphocyte interaction suggested that the resistance of B16-F10^Lr cells to destruction by syngeneic lymphocytes in vitro was due to the masking or absence of tumor-specific antigen(s) present on the lymphocyte-susceptible F10 cells.

¹ Research supported by National Cancer Institute Contract N01-CO-25423 with Litton Bionetics, Inc.

Received 6/ 8/77. Accepted 7/29/77.

This article has been cited by other articles:

				R. R. Langley and I. J. Fidler Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis Endocr. Rev., May 1, 2007; 28(3): 297 - 321. [Abstract] [Full Text] [PDF]

				M. Hejna, M. Raderer, and C. C. Zielinski Inhibition of Metastases by Anticoagulants J Natl Cancer Inst, January 6, 1999; 91(1): 22 - 36. [Abstract] [Full Text] [PDF]